Biomay to use VTU's yeast-based tech for its allergen pipeline

By Dan Stanton contact

- Last updated on GMT

Biomay to use VTU's yeast-based tech for its allergen pipeline

Related tags: Dna, Gene

Biomay has licensed a yeast-based expression system from fellow Austrian biotech VTU Technologies to use for the commercial production of its recombinant allergens.

The deal will see Biomay use VTU’s Pichia pastoris​ protein technology to generate expression strains for the commercial production of its allergy vaccine pipeline.

Recombinant allergens are generally not more difficult to express than other recombinant proteins, but are dependent on the complexity of the protein, Biomay’s CEO Hans Huber told this publication.

“If a protein is not expressible /producible with established systems such as E.coli, VTU´s Pichia Technology often succeeds,”​ he added.

Thomas Purkarthofer, Head of Business Development at VTU Technology, added his company’s technology “is composed of different elements such as platform strains with different genetic backgrounds, libraries of promoter variants and a set of proprietary expression enhancing helper proteins assisting the synthesis of a given target protein,”​ which, from a productivity angle, sets it apart from other expression platforms available.

“VTU´s experienced development team is capable of exploiting this technological potential by comparing thousands of strains in minimum time by applying elaborated lab protocols for strain generation and cultivation,”​ he explained to Biopharma-Reporter.com.

Like other methylotrophic yeasts, Pichia pastoris​ can be cultured to high cell densities within a short time and in reasonably strong methanol solutions. This coupled with VTU’s synthetic AOX1 promoter libraries, which fine tunes’ gene expression by selecting the best match for a range of different combinations of promoters, allows production yields of over 20g/L.

According to Purkarthofer, Biomay has been granted access on a product-by-product basis, and VTU will receive royalties based on sales of the recombinant allergens.

The announcement comes three months after VTU extended a deal with Boehringer-Ingelheim​ which is using the expression system for both its proprietary biologics and for its customers through its CMO business.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars